Search research articles
Contact Us
Filters
Showing results (331-340 of 347) with videos related to
Page
of 35
Sort By:
The Journal of Urology
|
July 21, 2009
Preliminary study of virtual reality and model simulation for learning laparoscopic suturing skills
Elspeth M McDougall, Surendra B Kolla, Rosanne T Santos, et al.
The Lancet. Respiratory Medicine
|
December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
Journal of Endourology
|
March 12, 2009
Evaluation of the outcomes of electrosurgical induced bowel injury treated with tissue glue/sealant versus sutured repair in a rabbit model
Geoffrey N Box, Hak J Lee, Jose Benito A Abraham, et al.
Cold Spring Harbor Molecular Case Studies
|
September 15, 2016
A de novo missense mutation in ZMYND11 is associated with global developmental delay, seizures, and hypotonia
Abby M Moskowitz, Newell Belnap, Ashley L Siniard, et al.
ACS Infectious Diseases
|
July 12, 2017
Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes
Mei-Ling Han, Hsin-Hui Shen, Karl A Hansford, et al.
The New England Journal of Medicine
|
October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating, Gautham Marigowda, Lucy Burr, et al.
International Journal of Environmental Research and Public Health
|
April 13, 2023
Cell Phone Radiation Exposure Limits and Engineering Solutions
Paul Héroux, Igor Belyaev, Kent Chamberlin, et al.
The New England Journal of Medicine
|
November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Peter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.
The New England Journal of Medicine
|
October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Jane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.
Lancet (London, England)
|
November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Page
of 35
Search research articles
Search
Showing results (331-340 of 347) with videos related to
Sort By:
Page
of 35
The Journal of Urology
|
July 21, 2009
Preliminary study of virtual reality and model simulation for learning laparoscopic suturing skills
Elspeth M McDougall, Surendra B Kolla, Rosanne T Santos, et al.
The Lancet. Respiratory Medicine
|
December 23, 2021
Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial
Sivagurunathan Sutharsan, Edward F McKone, Damian G Downey, et al.
Journal of Endourology
|
March 12, 2009
Evaluation of the outcomes of electrosurgical induced bowel injury treated with tissue glue/sealant versus sutured repair in a rabbit model
Geoffrey N Box, Hak J Lee, Jose Benito A Abraham, et al.
Cold Spring Harbor Molecular Case Studies
|
September 15, 2016
A de novo missense mutation in ZMYND11 is associated with global developmental delay, seizures, and hypotonia
Abby M Moskowitz, Newell Belnap, Ashley L Siniard, et al.
ACS Infectious Diseases
|
July 12, 2017
Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes
Mei-Ling Han, Hsin-Hui Shen, Karl A Hansford, et al.
The New England Journal of Medicine
|
October 19, 2018
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating, Gautham Marigowda, Lucy Burr, et al.
International Journal of Environmental Research and Public Health
|
April 13, 2023
Cell Phone Radiation Exposure Limits and Engineering Solutions
Paul Héroux, Igor Belyaev, Kent Chamberlin, et al.
The New England Journal of Medicine
|
November 8, 2019
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Peter G Middleton, Marcus A Mall, Pavel Dřevínek, et al.
The New England Journal of Medicine
|
October 19, 2018
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Jane C Davies, Samuel M Moskowitz, Cynthia Brown, et al.
Lancet (London, England)
|
November 5, 2019
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G M Heijerman, Edward F McKone, Damian G Downey, et al.
Page
of 35